ISG15 and viral infectious disease: SARS-CoV-2 Plpro antagonistic activity against ISG-15 might block the production of various cytokines involved in the activation of the innate immune response against viral infection, e.g., Type I IFN-β and chemokines such as CXCL10 and CCL5 [41,43].